Evidence map›Paper›PMID 10815799›Full record

ArticleOncogene2000

Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity.

Y Z Wang, W Wharton, R Garcia, A Kraker, R Jove, W J Pledger

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 110 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Y Z WangMolecular Oncology, Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
W Wharton
R Garcia
A Kraker
R Jove
W J Pledger
Molecular Oncology (United States) · USFlorida College · USMichigan Cancer Research Consortium · USMoffitt Cancer Center · US

Funding

SIGNAL TRANSDUCTION IN SRC ONCOGENESISR01CA055652 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI JOVE, RICHARD · 1992 to 2006
$1.9M
REGULATION OF CELL PROLIFERATION BY CYCLIN D1/PRADR01CA067360 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI PLEDGER, WARREN JACKSON · 1994 to 2002
$739k
NCI NIH HHS CA55652NCI NIH HHS CA67360
6 · The paper itself

Abstract

Members of the STAT family of transcriptional regulators modulate the expression of a variety of gene products that promote cell proliferation, survival and transformation. Although initially identified as mediators of cytokine signaling, the STAT proteins are also activated by, and thus may contribute to the actions of, polypeptide growth factors. To define the mechanism by which these factors activate STATs, we examined the process of Stat3 activation in Balb/c-3T3 fibroblasts treated with platelet-derived growth factor (PDGF). As STATs are activated by tyrosine phosphorylation, and as PDGF receptors are ligand-activated tyrosine kinases, we considered the possibility that Stat3 interacts with and is phosphorylated by PDGF receptors. We find that Stat3 associates with PDGF beta receptors in both the presence and, surprisingly, the absence of PDGF. Moreover, Stat3 was phosphorylated on tyrosine in PDGF beta receptor immunoprecipitates of PDGF-treated but not untreated cells. Although required, receptor activation was insufficient for Stat3 activation. When added to cells in combination with a pharmacologic agent (PD180970) that specifically inhibits the activity of Src family tyrosine kinases, PDGF did not activate Stat3 as monitored by electrophoretic mobility shift assay. PD180970 did not affect MAPK activation by PDGF or the JAK-dependent activation of Stat3 by interleukin-6. The necessity of Src activity for Stat3 activation by PDGF was further evidenced by data showing the presence of Src in complexes containing both Stat3 and PDGF beta receptors in PDGF-treated cells. These results suggest a novel mechanism of STAT activation in which inactive Stat3 pre-assembles with inactive PDGF receptors, and in response to ligand binding and in a manner dependent on Src kinase activity, is rapidly phosphorylated and activated. Additional data demonstrate that Src kinase activity is also required for PDGF stimulation of DNA synthesis in density-arrested cells.

Indexed as

3T3 CellsAnimalsCell CycleDNA-Binding ProteinsEnzyme InhibitorsMiceMice, Inbred BALB CPhosphorylationPlatelet-Derived Growth FactorReceptor, Platelet-Derived Growth Factor alphasrc-Family KinasesSTAT1 Transcription FactorSTAT3 Transcription FactorTrans-ActivatorsTyrosineDNA-Binding ProteinsEnzyme InhibitorsPlatelet-Derived Growth FactorReceptor, Platelet-Derived Growth Factor alphasrc-Family KinasesStat1 protein, mouseSTAT1 Transcription FactorStat3 protein, mouseSTAT3 Transcription FactorTrans-ActivatorsTyrosine

Identifiers

PMID10815799
OpenAlexW2312853461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.